AIM Vaccine Has Obtained Clinical Approval For Two Heavyweight Products, Creating New Growth Points For Performance
Date
12/26/2024 4:51:36 AM
(MENAFN- The Arabian Post) HONG KONG SAR – media OutReach Newswire – 20 December 2024 – AIM Vaccine (06660) has added good news to the research and development of its heavyweight single product. According to the announcement on December 19, the clinical trial approval for the Group's suspension culture quadrivalent influenza vaccine (MDCK cells) with new technological route and second generation of highly-effective absorbed tetanus vaccine have been recently obtained from [...]">
MENAFN26122024000152002308ID1109031463
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.